NZ583149A - Benzazepine compounds for the treatment of hepatitis c - Google Patents

Benzazepine compounds for the treatment of hepatitis c

Info

Publication number
NZ583149A
NZ583149A NZ583149A NZ58314908A NZ583149A NZ 583149 A NZ583149 A NZ 583149A NZ 583149 A NZ583149 A NZ 583149A NZ 58314908 A NZ58314908 A NZ 58314908A NZ 583149 A NZ583149 A NZ 583149A
Authority
NZ
New Zealand
Prior art keywords
methoxy
indolo
cyclohexyl
benzazepine
methyl
Prior art date
Application number
NZ583149A
Other languages
English (en)
Inventor
Scott W Martin
Carl P Bergstrom
Robert G Gentles
Kap-Sun Yeung
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NZ583149A publication Critical patent/NZ583149A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ583149A 2007-08-09 2008-08-01 Benzazepine compounds for the treatment of hepatitis c NZ583149A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95481407P 2007-08-09 2007-08-09
US4994408P 2008-05-02 2008-05-02
US12/180,994 US7652004B2 (en) 2007-08-09 2008-07-28 Compounds for the treatment of hepatitis C
PCT/US2008/071881 WO2009029384A2 (en) 2007-08-09 2008-08-01 Compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
NZ583149A true NZ583149A (en) 2011-07-29

Family

ID=40261456

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ583149A NZ583149A (en) 2007-08-09 2008-08-01 Benzazepine compounds for the treatment of hepatitis c

Country Status (18)

Country Link
US (1) US7652004B2 (cg-RX-API-DMAC7.html)
EP (1) EP2183252B1 (cg-RX-API-DMAC7.html)
JP (1) JP5465670B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100066492A (cg-RX-API-DMAC7.html)
CN (1) CN101821267B (cg-RX-API-DMAC7.html)
AR (1) AR067897A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008293845B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0814931A2 (cg-RX-API-DMAC7.html)
CA (1) CA2695781A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008002353A1 (cg-RX-API-DMAC7.html)
CO (1) CO6251359A2 (cg-RX-API-DMAC7.html)
EA (1) EA015978B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010001416A (cg-RX-API-DMAC7.html)
NZ (1) NZ583149A (cg-RX-API-DMAC7.html)
PE (1) PE20090618A1 (cg-RX-API-DMAC7.html)
TW (1) TW200906418A (cg-RX-API-DMAC7.html)
WO (1) WO2009029384A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000923B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. 5-5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2209789B1 (en) * 2007-11-20 2011-11-16 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2396329B1 (en) * 2009-02-11 2014-10-29 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
WO2012176717A1 (ja) * 2011-06-22 2012-12-27 セントラル硝子株式会社 ピラゾール化合物の製造方法
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
US7652004B2 (en) 2010-01-26
EA015978B1 (ru) 2012-01-30
PE20090618A1 (es) 2009-05-16
CO6251359A2 (es) 2011-02-21
TW200906418A (en) 2009-02-16
CN101821267B (zh) 2013-07-10
MX2010001416A (es) 2010-03-01
EA201000277A1 (ru) 2010-06-30
EP2183252B1 (en) 2015-01-14
KR20100066492A (ko) 2010-06-17
WO2009029384A2 (en) 2009-03-05
WO2009029384A3 (en) 2009-05-28
CL2008002353A1 (es) 2008-10-24
AR067897A1 (es) 2009-10-28
JP5465670B2 (ja) 2014-04-09
EP2183252A2 (en) 2010-05-12
CN101821267A (zh) 2010-09-01
AU2008293845B2 (en) 2013-02-14
CA2695781A1 (en) 2009-03-05
AU2008293845A1 (en) 2009-03-05
US20090074715A1 (en) 2009-03-19
BRPI0814931A2 (pt) 2015-02-03
JP2010535787A (ja) 2010-11-25
ZA201000923B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
EP2183252B1 (en) Compounds for the treatment of hepatitis c
AU2007211988B2 (en) HCV NS5B inhibitors
EP2024375B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7547690B2 (en) Compounds for the treatment of Hepatitis C
US7521443B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US20060166964A1 (en) Inhibitors of HCV replication
AU2007361468A1 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2280975B1 (en) 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c
CN116640156B (zh) Ripk1抑制剂
US8143243B2 (en) Compounds for the treatment of hepatitis C
EP2396329B1 (en) Compounds for the treatment of hepatitis c
HK1122814B (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed